BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1109 related articles for article (PubMed ID: 23134589)

  • 21. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
    Whiteley J; Iyer S; Candrilli SD; Kaye JA
    Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.
    Trask PC; Mitra D; Iyer S; Candrilli SD; Kaye JA
    Int J Hematol; 2012 May; 95(5):535-44. PubMed ID: 22461032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
    Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
    Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.
    Wu B; Liu M; Li T; Lin H; Zhong H
    Medicine (Baltimore); 2017 Jul; 96(29):e7445. PubMed ID: 28723754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
    Garg RJ; Kantarjian H; O'Brien S; Quintás-Cardama A; Faderl S; Estrov Z; Cortes J
    Blood; 2009 Nov; 114(20):4361-8. PubMed ID: 19729517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response dynamics in chronic-phase chronic myeloid leukemia.
    Mauro MJ
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):217-22. PubMed ID: 19525190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
    Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
    Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
    Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
    Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line therapy for chronic myeloid leukemia: new horizons and an update.
    Saglio G; Baccarani M
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):169-76. PubMed ID: 20511160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
    Erba HP; Pham DC; Zaiden R; Vu H; Tai S
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
    Signorovitch J; Ayyagari R; Reichmann WM; Wu EQ; Chen L
    Cancer Treat Rev; 2014 Mar; 40(2):285-92. PubMed ID: 24112812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
    Kantarjian H; Shah NP; Hochhaus A; Cortes J; Shah S; Ayala M; Moiraghi B; Shen Z; Mayer J; Pasquini R; Nakamae H; Huguet F; Boqué C; Chuah C; Bleickardt E; Bradley-Garelik MB; Zhu C; Szatrowski T; Shapiro D; Baccarani M
    N Engl J Med; 2010 Jun; 362(24):2260-70. PubMed ID: 20525995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.
    Adel A; Abushanab D; Hamad A; Abdulla M; Izham M; Yassin M
    Cancer Control; 2021; 28():10732748211001796. PubMed ID: 33887995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
    Griffin JD; Guerin A; Chen L; Macalalad AR; Luo J; Ionescu-Ittu R; Wu EQ
    Curr Med Res Opin; 2013 Jun; 29(6):623-31. PubMed ID: 23517347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.